Mycosis fungoides
Methodology & AI Transparency ⓘ
Mycosis fungoides Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Mycosis fungoides is an ICD-10-CM indexed diagnosis (C84.00) within Cancer, Oncology & Supportive Care.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C84.00 for Mycosis fungoides clinical workups.
- 3 Typical cash cost range: Differential triage of Mycosis fungoides (C84.00) utilizes radiation) paired with in Mycosis fungoides (C84.00: proactive supportive symptom).
- 4 Top reported side effects / signs: Follow-up benchmark in Mycosis fungoides: maintaining Complete Blood Count in Mycosis fungoides (C84.00: (ANC, Hemoglobin, Platelets)) within Safe hematologic reserve (C84.00).
Ask our AI Specialists anything about Mycosis fungoides
What Is Mycosis fungoides?
Mycosis fungoides is an ICD-10-CM indexed diagnosis (C84.00) within Cancer, Oncology & Supportive Care. Clinical evaluation centers on radiation) paired with in Mycosis fungoides (C84.00: proactive supportive symptom) alongside serial Complete Blood Count in Mycosis fungoides (C84.00: (ANC, Hemoglobin, Platelets)) tracking (Safe hematologic reserve (C84.00)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Mycosis fungoides (C84.00) features tumor-suppressor loss enabling in Mycosis fungoides (C84.00: clonal proliferation). therapeutic stabilization in cancer & oncology is verified against Comprehensive Metabolic & in Mycosis fungoides (C84.00: Organ Function Panel).
Common Symptoms & Clinical Signs
- • Presentation of Mycosis fungoides (C84.00): unintended weight loss [Mycosis fungoides C84.00]
- • Secondary Mycosis fungoides clinical sign: unexplained bleeding, chronic in Mycosis fungoides (C84.00: hoarseness/cough, or progressive)
- • Symptom flares in Mycosis fungoides correlating with Complete Blood Count in Mycosis fungoides (C84.00: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C84.00)
- • Functional cancer & oncology impact requiring radiation) paired with in Mycosis fungoides (C84.00: proactive supportive symptom) evaluation (C84.00)
Mycosis fungoides Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C84.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Complete Blood Count in Mycosis fungoides (C84.00: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C84.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Mycosis fungoides (C84.00: Organ Function Panel) | Preserved renal/hepatic clearance (C84.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Mycosis fungoides (C84.00: Genomic Staging) | Guideline-concordant surveillance (C84.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mycosis fungoides
Treatment selection for Mycosis fungoides depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mycosis fungoides)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Skin-applied Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in: What a 1,655-Participant Study Found Applied to the skin efinaconazole 10% showed favorable efficacy/safety in White, Asian, and Black participants with mild-to-moderate onychomycosis. Journal of drugs in dermatology : JDD • 2026-01-01 • Phase III Randomized Trial | N = 1,655 | 96/100 | PMID 41493257 ↗ |
| New Insights on Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term: What a 709-Participant Study Found Adjuvant NIVO for high-risk MIUC was associated with a higher cure fraction than PBO in the ITT and PD-L1 ≥1% populations. Clinical genitourinary cancer • 2025-06-15 • Phase III Randomized Trial | N = 709 | 93/100 | PMID 40204616 ↗ |
| New Insights on Quality-adjusted survival in patients with metastatic colorectal cancer treated: What a 461-Participant Study Found Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC. ESMO open • 2025-03-15 • Phase III Randomized Trial | N = 461 | 93/100 | PMID 39985889 ↗ |
| New Insights on Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia:: What a 447-Participant Study Found Common any-grade side effects (≥10% incidence in any arm) were diarrhea (87.0% vs 32.9%), febrile neutropenia (52.8% vs 49.3%), and nausea (52.5% vs 31.5%). Blood advances • 2022-07-26 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 35413116 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Efinaconazole 10% skin-applied Solution for Treatment of Efinaconazole 10% solution showed similar efficacy/safety in participants aged ≥ 65 years to the overall phase 3 population, despite potential age-related nail changes. Mycoses • 2025-05-15 • Phase III Randomized Trial | N = 162 | 88/100 | PMID 40396391 ↗ |
Mycosis fungoides Patient Community & “People Like Me” Threads
Filter Mycosis fungoides community threads and patient logs by age, biological sex, dosage, and treatment duration.